---
title: "Foyou Pharma: Pioglitazone and Metformin Tablets (15mg/850mg) have obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257497907.md"
description: "Foyou Pharma recently obtained the drug registration certificate for Pioglitazone and Metformin Tablets (15mg/850mg) issued by the National Medical Products Administration, approving the production of this drug. This drug is suitable for patients with type 2 diabetes, especially those who do not respond well to existing treatments. The original research company is Takeda Pharmaceutical Company Limited, and this drug has not yet been launched in China"
datetime: "2025-09-16T08:36:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257497907.md)
  - [en](https://longbridge.com/en/news/257497907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257497907.md)
---

# Foyou Pharma: Pioglitazone and Metformin Tablets (15mg/850mg) have obtained the drug registration certificate

According to the Zhitong Finance APP, Foyou Pharma (601089.SH) announced that it has recently received the "Drug Registration Certificate" (Certificate No.: 2025S02764) issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for Pioglitazone Metformin Tablets (15mg/850mg) (Specification: Each tablet contains 15mg of Pioglitazone Hydrochloride (calculated as C₁₉H₂₀N₂O₃S) and 850mg of Metformin Hydrochloride) (hereinafter referred to as "the drug"), approving the production of this drug.

The original manufacturer of Pioglitazone Metformin Tablets (15mg/850mg) is Takeda Pharmaceutical Company Limited, which was approved for marketing in the United States in August 2005. Currently, the original manufacturer's Pioglitazone Metformin Tablets have not been launched in China. This product is suitable for patients with type 2 diabetes who are currently using a combination of Pioglitazone Hydrochloride and Metformin Hydrochloride for treatment based on dietary control and exercise, or for type 2 diabetes patients whose blood sugar control is poor after treatment with Metformin Hydrochloride alone

### Related Stocks

- [601089.CN](https://longbridge.com/en/quote/601089.CN.md)

## Related News & Research

- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [PRECIOUS-Gold falls more than 2% as Treasury yields, dollar weigh amid inflation concerns](https://longbridge.com/en/news/286943432.md)
- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)